Search
Insulin argine
go.drugbank.com/drugs/DB11564ExperimentalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersInsulin peglispro
go.drugbank.com/drugs/DB11567InvestigationalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersVenetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetocl...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine. Many patients with Parkinson’...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsAmenamevir
go.drugbank.com/drugs/DB11701InvestigationalAmenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersTalinolol
go.drugbank.com/drugs/DB11770InvestigationalTalinolol has been investigated for the basic science of Gastrointestinal Motility Disorder.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPazufloxacin
go.drugbank.com/drugs/DB11774InvestigationalPazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAllicin
go.drugbank.com/drugs/DB11780InvestigationalAllicin has been used in trials studying the treatment of Follicular Lymphoma.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsRelugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates